Skip to main content

Table 3 Safety overview

From: Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study

Patients, n (%)

Safety analysis set (N = 324)

Any AEa

24 (7.4)

Ocular AEsb

18 (5.6)

 Cataract

3 (0.9)

 Conjunctival hemorrhage

3 (0.9)

Treatment-related ocular AEs

5 (1.5)

Serious ocular AEs

7 (2.2)

Treatment-related serious ocular AEs

2 (0.6)

Non-ocular AEs

6 (1.9)

Treatment-related non-ocular AEs

0

Serious non-ocular AEs

2 (0.6)

Deathsc

2 (0.6)

  1. aAEs are those reported if they started after the first IVT-AFL injection and not later than 30 days after the last IVT-AFL injection. If no unambiguous allocation is possible because of missing parts of the AE start date for example, the AE will be treated as an AE (worst case scenario)
  2. bOcular AEs reported by preferred term in  ≥ 3 patients
  3. cOne patient died of myocardial infarction, and 1 patient died of prostate cancer
  4. AE adverse event, IVT-AFL intravitreal aflibercept